Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III <i>BRAF</i> V600–mutant melanoma: Five-year analysis of COMBI-AD.
Axel Hauschild(University Hospital Schleswig-Holstein), Dirk Schadendorf(Essen University Hospital), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Kohinoor Dasgupta(Heidelberg University), Monique Tan(Heidelberg University), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Eduard Gasal, Georgina V. Long(The University of Sydney), James Larkin(Royal Marsden NHS Foundation Trust), Laurent Mortier, Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), Caroline Robert(Université Paris-Sud), John M. Kirkwood(UPMC Hillman Cancer Center), Victoria Atkinson(Greenslopes Private Hospital), Mario Mandalà(University of Perugia)
Cited by 23
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k